Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx Plans Must Calculate Beneficiary Spending Themselves – CMS

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency is considering two options for implementing rules regarding seniors’ true out-of-pocket spending (TrOOP) on prescription drugs. TrOOP cost-tracking could be the responsibility of either the Medicare drug plans or a CMS “facilitation contractor.”

You may also be interested in...



Medicare Rx Implementing Regs Open For Comment Until October

Proposed rules for Title I (Part D drug benefit) and Title II (Medicare Advantage) of the Medicare Modernization Act are unveiled at an HHS press conference. Final regs will be done by early 2005, "if not sooner," CMS Administrator McClellan says.

Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims

FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.

Efficacy Differences Within Drug Classes Unsupported By Data, FDA's Temple Says

Studies that look for differences in efficacy among members of the same drug class are only performed when necessary for approval, CDER Office of Medical Policy Director Temple tells DIA. While questioning the introduction of "follow-on" compounds, Temple also highlights AstraZeneca's success in achieving a more optimal dose for Nexium.

Topics

UsernamePublicRestriction

Register

PS057778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel